NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2003 (Third Quarter of Fiscal 2003)
Business Overview: The Company engages in the formulation, manufacturing, and packaging of vitamins and nutritional supplements. Operations are divided into a core contract manufacturing business and a direct-to-consumer (DTC) business (Dr. Cherry's Pathway to Healing and the new Jennifer O'Neill Signature Line).

Key Financial Metrics

(All figures in thousands, except per share data)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7% ($13.8M) for the quarter and 13% ($39.9M) for the nine-month period compared to the prior year. Growth was driven by a 24% increase in DTC sales (quarter) and a 9% increase in core sales (nine months).
• Profitability Improvement: The Company returned to operating profitability. Operating income improved from a loss of $59,000 in the prior year quarter to $211,000. For the nine-month period, operating income turned from a $244,000 loss to an $869,000 gain.
• Margin Expansion: Gross profit margin improved to 23.9% from 22.5% (quarter) and 21.5% (nine months), attributed to fixed cost leverage from higher sales volumes.
• Expense Management: Selling, General & Administrative (SG&A) expenses increased 4% for the quarter and 10% for the nine months, primarily due to DTC media costs and personnel. However, SG&A as a percentage of sales decreased to 21.7% for the nine-month period.
• One-Time Items: Proceeds from the Vitamin Antitrust Litigation were $0 for the current quarter and $225,000 for the nine-month period, compared to $1,000,000 in the same periods of the prior year. The litigation has been fully settled.

Guidance, Outlook, and Risks

• Outlook: Management anticipates near-term consistent operating profitability driven by moderate sales growth. Strategy focuses on expanding the DTC business (new product lines, media markets) and securing new core customers.
• Liquidity: The Company entered a new $6.5 million credit facility in October 2002 ($4M line of credit, $2.5M term loan). As of March 31, 2003, $3.8 million was available under the line of credit, and the term loan balance was $2.3 million. Management believes current cash and credit facilities are sufficient for near-term needs.
• Key Risks:
  • Customer Concentration: Two customers accounted for 70% of net sales for the nine months ended March 31, 2003. Loss of either would have a material adverse impact.
  • Supplier Concentration: Two suppliers accounted for 45% of raw material purchases.
  • Regulatory: Subject to FDA and FTC regulations regarding dietary supplements; potential for new labeling or manufacturing requirements.
  • Key Personnel: DTC business relies heavily on the visibility of key personalities (Dr. Cherry, Jennifer O'Neill).

Investor Verification Checklist

• Customer Dependency: Verify the stability of contracts with the two major customers representing 70% of revenue.
• Antitrust Proceeds: Confirm that the $225,000 received in the current period represents the final settlement and no further litigation income is expected.
• DTC Cost Structure: Monitor the sustainability of DTC growth relative to the increasing media and fulfillment costs driving SG&A expenses.
• Debt Covenants: Review the specific eligibility requirements for the $4 million line of credit to ensure continued access to liquidity.
• Inventory Levels: Assess the $8.5 million inventory balance against sales velocity, particularly given the concentration of raw material suppliers.